Tambiciclib Triplet Shows Preliminary Activity After Venetoclax Failure
SELLAS disclosed Phase 2 results on November 4 for tambiciclib (SLS009) with azacitidine and venetoclax in relapsed or refractory AML after prior venetoclax. This is a numerical data disclosure ahead of a December poster,…
